Bites from the brown recluse spider (BRS) can cause extreme pain. We propose cytokine release as a cause of the discomfort and a central mechanism through glial cell upregulation to explain measured pain levels and time course.
Twenty-three BRS bites were scored at a probable or documented level clinically, and an enzyme-linked immunosorbent assay was used to confirm the presence of BRS venom. The mean (SD) pain level in these cases 24 hours after the spider bite was severe: 6.74 (2.75) on a scale of 0 to 10. Narcotics may be needed to provide relief in some cases. The difference in pain level by anatomic region was not significant. Escalation observed in 22 of 23 cases, increasing from low/none to extreme within 24 hours, is consistent with a cytokine pain pattern, in which pain increases concomitantly with a temporal increase of inflammatory cytokines.
Conclusions and Relevance
These findings in BRS bites support the hypothesis of cytokine release in inflammatory pain. A larger series is needed to confirm the findings reported here. The extreme pain from many BRS bites motivates us to find better prevention and treatment techniques.
Pain from the bite of the brown recluse spider (BRS) can be extreme. One case with extreme pain is reported herein to illustrate the extent of BRS bite distress. We analyze the temporal pattern and severity of pain in cases of BRS bites confirmed both clinically and by detection of BRS venom by enzyme-linked immunosorbent assay (ELISA). We describe a typical time course for pain evolution and chart the pain intensity against anatomic BRS bite locations. These findings support the hypothesis of cytokine release in inflammatory pain.
A woman in her 20s noted a slight sensation similar to a mosquito bite on the medial knee surface. Within 24 hours, the pain level increased to 8 or 9 on a scale of 0 to 10, causing a noticeable limp with ambulation. Laboratory findings at an emergency department were unremarkable other than a mild left shift in her white blood cell differential count (neutrophils, 81.9% [normal, 40%-80%]). An oxycodone-acetaminophen combination was prescribed.
Less than a week after the bite, her lesion remained painful and pruritic (Figure 1A). The lesion showed 3 loxoscelism features: gravitationally dependent spread, central pallor, and the red, white, and blue sign (ecchymosis, ischemic pallor, and erythema).1 Additionally, 7 negative signs that decrease the likelihood of a BRS bite were all absent: (1) early ulceration (before 1 week), (2) large ulceration (>10-cm diameter), (3) lymphadenopathy, (4) central erythema, (5) purulence, (6) more than 2 lesions, and (7) raised red center.2 Urinalysis findings were normal. ELISA quantization of BRS venom from wound swabs showed a mean (SD) presence of 0.21 (0.13) ng of venom; 2 swabs from the patient to establish an immunoreactivity threshold showed 0.089 ng.3 The patient noted persistent pain (8-9 on a scale of 0-10), only minimally relieved by lidocaine patches, and requested a refill of the oxycodone-acetaminophen combination to enable her to continue working.
A, Five days after the BRS bite, gravitational spread can be seen on the lower right of the lesion, as can the red, white, and blue sign throughout (ecchymosis, ischemic pallor, and erythema). B, Eight days after the bite, gravitational spread and red, white, and blue sign are still present. C, Forty-seven days after the BRS bite, the 2 bite sites are clearly separated.
About a week after the bite, the patient had persistent aching and additional areas of erythema (Figure 1B). Urine dipstick testing showed a trace of blood and no urobilinogen, a finding interpreted as mild intravascular hemolysis. Additional lidocaine patches and oxycodone-acetaminophen were prescribed.
A month and a half after the initial bite, 2 crusted lesions, one measuring 5 cm, the other 2 cm across the largest dimension, remained unhealed (Figure 1C). Erythema surrounded both lesions; a clear yellow exudate was present. The patient was treated with saline soaks alternated with hydrocolloid moisture-retentive wound dressing (Duoderm GCF; ConvaTec Inc). The patient complained of severe pain relieved only with oxycodone-acetaminophen. For 2 months, she continued taking the opioid-analgesic combination, allowing her to continue working. By approximately 3 months after the bite, the lesions had healed.
Data on pain in spider bites were collected as part of National Institutes of Health study SBIR R44 AR-055683 according to a protocol approved by the institutional review board of Phelps County Regional Medical Center, Rolla, Missouri. Photographs, swabs of the bite sites, and clinical data on 175 patients with possible BRS bites were collected. Of these cases, 74 were rated as either probable (n=68) or documented (n=6) by the revised clinical criteria of Rader et al.2 An experimental ELISA test for BRS venom3 was performed on 56 of these probable and documented cases. The ELISA result was positive in 46 of these cases. Thus, 46 cases were considered likely BRS bites by both clinical and experimental laboratory criteria. For 23 cases, the patient’s recollection of the pain at the time of the bite and 24 hours later were recorded on a numerical scale of 0 to 10.
The mean (SD) pain score at the time of the bite on the 0 to 10 scale was 2.37 (2.84); after 24 hours, it was 6.74 (2.75). Of the 23 patients with recorded pain scores at the time of the bite, 12 (52%) had pain; 11 (48%) had no pain. Of the 23 patients scored at 24 hours, 22 (96%) had pain.
Mean (SD) ELISA venom quantization for those with a mild pain score (0-3) was 0.13 (0.06) ng. ELISA quantization for those with at least moderate score (4-10) was 0.25 (0.29) ng. The difference suggests a nonsignificant trend of recovering more venom with at least moderate pain. No trend for venom recovery was found among higher pain score subgroups.
The anatomic location of the BRS bites was also considered as a factor affecting severity. The 24-hour pain scores are shown grouped by anatomic region in Figure 2. Pain in 7 BRS bite cases was scored 9 or 10 of 10; anatomic locations for these bites were widespread (Figure 2). Average scores at 24 hours for 23 scored bites were calculated for 5 different anatomic regions. No significant differences in discomfort were found among the anatomic regions, with each region within the standard deviation of the average pain score of 6.74 (2.75).
Illustrated are mean (SD) pain scores from a total of 23 “probable” BRS bites with positive ELISA findings (enzyme-linked immunosorbent assay) by anatomic region: trunk and proximal and distal upper and lower extremities (colors are set solely for greater ease of visual distinction between the regions). Numbers in circles represent the scores and anatomic locations of the 7 very high pain scores (9 or 10 on a scale of 0-10, 10 being the most painful).
Diagnosis of a BRS bite is often difficult because other diagnoses mimic these bites. Initially asymptomatic, the bites may evolve into very painful, slowly resolving scarring lesions. Two previous studies have recorded the frequency of pain in suspected BRS bite cases; neither study was limited to cases with a high level of certainty. Clowers4 in Arkansas noted pain in 69% of 39 lesions consistent with BRS bites.4 The medical record review included cases if the assessment was “probable” or “possible” BRS bite. The criteria for these categories and the number in each category were not discussed.4 Cacy and Mold5 in Oklahoma noted pain in 60% of 149 suspected BRS bites. After initial assessment and direct observation of the evolution of the lesions until healed, 9% of the Oklahoma lesions were believed to be definite BRS bites, 40% probable BRS bites, and 22% possible BRS bites.
Oldenmenger et al,6 reviewing articles using the 0 to 10 numerical pain scale to establish moderate and extreme pain, found that scores of 5 and 7 were optimal cut points for moderate and severe levels, respectively. Thus the average pain score for spider bites is close to the threshold of severe pain (6.74 vs 7.0). Since only 4 of 23 patients in the present study scored lower than 5, we observed 19 of 23 patients (83%) with at least moderate pain.
There is no universal agreement on the best descriptions for numerical pain ratings 0 to 10. An attempt to describe such scales was compiled from multiple sources by Richards7 at HealthCentral.com, and the following describe extreme pain:
7 – Severe pain that dominates your senses and significantly limits your ability to perform normal daily activities or maintain social relationships. Interferes with sleep.
8 – Intense pain. Physical activity is severely limited. Conversing requires great effort.
9 – Excruciating pain. Unable to converse. Crying out and/or moaning uncontrollably.
10 – Unspeakable pain. Bedridden and possibly delirious. Very few people will ever experience this level of pain.
For our cases that included comments along with the pain score, overall agreement with this scale is noted: “My tail end was on fire [pain score, 8 of 10].” “Burning, throbbing, feels like a shock [pain score, 9 of 10].” “Constant throb like on fire [pain score, 10 of 10].”
The level of pain was recorded for both the time of the bite and 24 hours later. On a scale of 0 to 10, the mean (SD) pain score at the time of the bite was 2.37 (2.84); after 24 hours, it was 6.74 (2.75). An increase in pain from the time of the bite over the next 24 hours was noted in all but 1 case. For this case, the pain score was 0 at the time of the bite and 0 after 24 hours.
These clinical results showing delay in pain development are in accord with the delay in cytokine release in an experimental study by Gomez et al8 on the release of a cytokine, interleukin 8 (IL-8), after experimental inoculation of BRS venom in human epithelial cells. The IL-8 level was shown to be over 10 times higher at 8 hours than it was at 0.5 or 2 hours. The amounts released at the earlier times did not differ from background.8 Interleukin 8 has been associated with pain in several studies9- 11 and has been proposed as a pain biomarker.11 One explanation for the presence of 0 pain in some bites can be found in the same in vivo study by Gomez et al8: IL-8 is not released above background when the concentration of BRS venom in the experimental epithelial model is below 0.5 µg/mL, establishing a floor of venom concentration below which cytokine release (and subsequent pain) is not expressed.8
Besides cytokine release, BRS venom may cause pain via other peripheral pathways, including direct action on peripheral nerves by sphingomyelinase or even peripheral nerve transport analogous to that of tetanus toxin.
Pain in the cases studied here has been classified as inflammatory owing to associated peripheral tissue damage.12,13 Recent research has shown links between chronic pain and cytokine signals to the CNS, in particular astrocytes and satellite glial cells, 2 types of glial cells within the CNS, and in some studies a third type of glial cell—microglia.12,14 Cytokines, including interleukins and tumor necrosis factor have been shown to upregulate these glial cells. Thus the time course of the pain, showing marked increase over the first day, is entirely consistent with the direct inflammatory cytokine release found experimentally.8 These findings could have therapeutic relevance for cytokine-related pain. Minocycline, an inhibitor of microglia, has been shown to reduce inflammatory pain.14
The level of discomfort from different anatomic sites was relatively constant. The bites that were scored 9 or 10 are in widely scattered locations (Figure 2). These findings are consistent with the centrally acting mechanism for inflammatory pain. Incorporating our findings in a recent model of the mechanism for the inflammatory variety,12,14 we hypothesize that BRS venom triggers cytokine release, which causes upregulation of pain receptor glial cells. Pain signals travel via the spinothalamic tract; the thalamus acts as way station for the signal; and finally the cerebrum is made aware of severe pain at a specific site. Because cytokine release is significant for all Loxosceles reclusa bites with more than an estimated 0.5 µg of venom, pain is severe after 24 hours; it is largely independent of bite location; and it persists at a high level as long as cytokine levels remain high. After some time, the inflammatory pain subsides, and a more moderate level is driven by chronic tissue injury. Pain in older healing spider bite wounds was not investigated. Anecdotal evidence suggests that discomfort levels with time approach those in chronic leg ulcers: 2.9 of 10.15
The ELISA used to detect BRS venom at the bite site is still undergoing modification, as shown in the first case, in which 2 bite-site determinations differed. Overall, 46 of 56 probable cases showed venom at the bite site by ELISA. We considered the possibility that the requirement of a positive ELISA finding in addition to the requirement of clinically probable or documented bites may have changed the average pain scores. For the 10 probable or documented bites with a negative ELISA finding, mean (SD) pain scores at 24 hours were 6.6 (2.3), similar to the score of 6.74 (2.75) found when both positive ELISA result and a clinically probable or documented bite were present. A weakness of this study is the lack of objective measurement of cytokine levels. Inferences regarding the relationship of peripheral pain to CNS mechanisms and the pathways activated by BRS venom are hypothesized but not documented.
Pain is a prominent feature of BRS bites and can be very severe, 9 or 10 on a scale of 10 in 7 of 23 cases.
Providing relief of discomfort for victims of a BRS bite is an important component of management.
Pain from a BRS bite follows a cytokine release pain pattern, starting low at the time of the bite and typically becoming severe after 1 day, regardless of bite location.
RICE therapy (rest, ice, compression, and elevation) and lidocaine patches should be tried first for pain relief. Opioid agonists may be a useful treatment adjunct for some patients.
Prevent spider bites by keeping the bed away from the wall and checking clothes that have not been worn recently.
Corresponding Author: William V. Stoecker, MD, MS, Stoecker & Associates, 10101 Stoltz Dr, Rolla, MO 65401 (email@example.com).
Published Online: July 30, 2014. doi:10.1001/jamadermatol.2014.605.
Author Contributions: Ms Payne and Dr Stoecker had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Payne, Rader, Dyer, Stoecker.
Acquisition, analysis, or interpretation of data: Payne, Schilli, Meier, Rader, Mold, Green, Stoecker.
Drafting of the manuscript: Payne, Rader, Stoecker.
Critical revision of the manuscript for important intellectual content: Payne, Schilli, Meier, Rader, Dyer, Mold, Green, Stoecker.
Statistical analysis: Payne, Schilli, Meier, Stoecker.
Obtained funding: Stoecker.
Administrative, technical, or material support: Green, Stoecker.
Study supervision: Stoecker.
Conflict of Interest Disclosures: Drs Green and Stoecker are coholders of a patent on an ELISA BRS envenomation test. Dr Stoecker is founder and CEO of SpiderTek, manufacturer of spider tests and traps. Mss Payne, Schilli, and Meier and Mr Rader are employees of SpiderTek.
Funding/Support: This study was supported in part by SpiderTek and made possible by phase 1 and 2 awards R43 AR055863-01 and R44 AR055863-02 from the National Institutes of Health.
Role of the Sponsor: The sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Disclaimer: The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of NIH.
Additional Contributions: We appreciate the cooperation of those who volunteered to be included in this study. Participants received no compensation for their involvement.
Payne KS, Schilli K, Meier K, Rader RK, Dyer JA, Mold JW, Green JA, Stoecker WV. Extreme Pain From Brown Recluse Spider BitesModel for Cytokine-Driven Pain. JAMA Dermatol. 2014;150(11):1205-1208. doi:10.1001/jamadermatol.2014.605